{"news_desk": "Business", "print_page": "3", "section_name": "Business Day", "subsection_name": null, "byline": {"original": "By ANDREW POLLACK", "person": [{"rank": 1, "role": "reported", "firstname": "Andrew", "organization": "", "lastname": "POLLACK"}]}, "abstract": "Valeant Pharmaceuticals says it expects 2015 revenue of $10.4 billion to $10.5 billion, down from earlier forecast of $11 billion to $11.2 billion; earnings per share are forecast at $10.23 to $10.33.", "type_of_material": "News", "word_count": "879", "lead_paragraph": "While the company gave no reason in a statement announcing the revised forecast, it has been dealing with controversies over its pricing and distribution.", "pub_date": "2015-12-17T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Valeant Pharmaceuticals Cuts Earnings and Sales Forecasts", "print_headline": "Valeant Cuts Its Forecast for Earnings and Sales"}, "snippet": "While the company gave no reason in a statement announcing the revised forecast, it has been dealing with controversies over its pricing and distribution.", "multimedia": [{"height": 126, "url": "images/2015/12/17/business/17valeant-web1/17valeant-web1-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/12/17/business/17valeant-web1/17valeant-web1-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 397, "url": "images/2015/12/17/business/17valeant-web1/17valeant-web1-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "397", "xlarge": "images/2015/12/17/business/17valeant-web1/17valeant-web1-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/12/17/business/17valeant-web1/17valeant-web1-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/12/17/business/17valeant-web1/17valeant-web1-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/12/17/business/valeant-lowers-guidance-investors-meeting.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Valeant Pharmaceuticals International Inc", "name": "organizations"}, {"rank": "2", "is_major": "N", "value": "Company Reports", "name": "subject"}, {"rank": "3", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}], "blog": [], "_id": "56716a4938f0d803bb110e81", "source": "The New York Times"}